The American Heart Assn. calls them "game changers." Oprah Winfrey says they're "a gift." Science magazine anointed them the "2023 Breakthrough of the Year." Americans are most familiar with their brand names: Ozempic, Wegovy, Mounjaro, Zepbound. They are the medications that have revolutionized weight loss and raised the possibility of reversing the country's obesity crisis. Obesity — like so many diseases — disproportionately affects people in racial and ethnic groups that have been marginalized by the U.S. healthcare system. A class of drugs that succeeds where so many others have failed would seem to be a powerful tool for closing the gap. Instead, doctors who treat obesity, and the serious health risks that come with it, fear the medications are making this health disparity worse. As Israel on Monday weighed its response to Iran's stunning attacks this weekend, the U.S. is privately telling officials there: If Israel strikes back militarily, it will do so alone.